13c-pyruvate
Small moleculeexperimentalImaging agent
Clinical trial activity
38 trials · 20 clinical orgs · 0 marketing orgs
Phase 1
24
Phase 2
15
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2013 (NCT01807702)
Timeline
Indications
Studied for
- Brain Injuries, Traumatic · Phase 1
- Brain Neoplasms · Phase 1
- Breast Neoplasms · Phase 2
- Carcinoma, Neuroendocrine · Phase 2
- Carcinoma, Renal Cell · Phase 2
- Carcinoma, Squamous Cell · Phase 1
- Cardiovascular Diseases · Phase 2
- Endometrial Neoplasms · Phase 2
- Fatty Liver · Early Phase 1
- Genital Neoplasms, Female · Phase 2
- Glioblastoma · Phase 1
- Glioma · Phase 1
- Healthy Volunteers · Phase 2
- Heart Failure · Phase 2
- Human Papillomavirus Viruses · Phase 1
- Kidney Neoplasms · Phase 2
- Lymphoma · Phase 2
- Meningioma · Phase 1
- Metabolic Syndrome · Phase 2
- Metabolism · Early Phase 1
- Mutation · Phase 1
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 2
- Neuroendocrine Tumors · Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Cyst · Phase 1
- Pancreatic Neoplasms · Phase 2
- Papilloma · Phase 1
- Prostatic Neoplasms · Phase 2
- Sarcoma · Phase 2
- Subarachnoid Hemorrhage · Phase 1
- Thyroid Neoplasms · Early Phase 1
- Uterine Cervical Neoplasms · Phase 2
- Warburg Effect, Oncologic · Phase 1/Phase 2
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 13-carbon
Oral
No
Parenteral
No
Topical
No
Also known as
- 13c-pyruvate
- 13c-pyruvate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05866679 | Phase 1 | Nov 30, 2024 | University of Texas at Houston |
| NCT06645691 | Phase 2 | Oct 17, 2024 | Government of Singapore |
| NCT06384222 | Phase 2 | Sep 30, 2024 | University of California, San Francisco |
| NCT06391034 | Phase 2 | Sep 24, 2024 | National Cancer Institute (NCI), University of California, San Francisco |
| NCT05697406 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2024 | University of Maryland |
| NCT05805358 | Phase 2 | Nov 1, 2023 | Chang Gung University |
| NCT06103201 | Phase 1 | Oct 26, 2023 | University of Maryland |
| NCT06014905 | Phase 1 | Sep 1, 2023 | General Electric, National Institutes of Health (NIH), University of California, San Francisco |
| NCT05873699 | Phase 1 | Aug 18, 2023 | University of Texas at Houston |
| NCT05746208 | Phase 2 | Jul 17, 2023 | Merck, University of California, San Francisco |
| NCT05599048 | Phase 1/Phase 2 (Phase 2) | Dec 15, 2022 | National Cancer Institute (NCI), National Institutes of Health (NIH), Sigma-Aldrich, University of California, San Francisco |
| NCT05600361 | N/A | Nov 1, 2022 | Chang Gung University |
| NCT05472220 | Phase 1 | Nov 1, 2022 | Novartis, University of California, San Francisco |
| NCT05396118 | Phase 2 | May 18, 2022 | University of Copenhagen |
| NCT05041166 | Phase 1 | Sep 1, 2021 | Memorial Sloan-Kettering Cancer Center |
| NCT04951921 | Phase 2 | Jul 15, 2021 | Chang Gung University, Government of Taiwan |
| NCT04698564 | Phase 2 | Dec 1, 2020 | University of Maryland |
| NCT04656431 | Phase 1 | Oct 30, 2020 | National Cancer Institute (NCI), University of California, San Francisco |
| NCT04565327 | Phase 2 | Aug 12, 2020 | University of California, San Francisco |
| NCT04589624 | Early Phase 1 (Phase 1) | Aug 12, 2020 | National Cancer Institute (NCI), University of Texas at Houston |
Showing 20 of 38 trials
Page 1 / 2
Organizations
Research & Development (20)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of California, San Francisco | Academic/Hospital | 13 | 13 | 2 | 2017 |
| National Cancer Institute (NCI) | Government | 9 | 0 | 2 | 2018 |
| The University of Texas, Dallas | Academic/Hospital | 5 | 5 | 1 | 2018 |
| University of Texas at Houston | Academic/Hospital | 5 | 5 | 2 | 2018 |
| University of Maryland | Academic/Hospital | 4 | 4 | 2 | 2020 |
| Chang Gung University | Academic/Hospital | 3 | 3 | 2 | 2021 |
| National Institutes of Health (NIH) | Government | 3 | 0 | 2 | 2018 |
| University of Toronto | Academic/Hospital | 3 | 3 | 1 | 2016 |
| General Electric | For profit | 2 | 0 | 1 | 2017 |
| Sigma-Aldrich | For profit | 2 | 0 | 2 | 2017 |
| Advanced Imaging Research Center | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Government of Singapore | Government | 1 | 1 | 1 | 2024 |
| Government of Taiwan | Government | 1 | 0 | 1 | 2021 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Merck | For profit | 1 | 0 | 1 | 2023 |
| Novartis | For profit | 1 | 0 | 1 | 2022 |
| Philips | For profit | 1 | 0 | 1 | 2017 |
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Copenhagen | Academic/Hospital | 1 | 1 | 1 | 2022 |
| University of Florida | Academic/Hospital | 1 | 1 | 1 | 2013 |
20 organizations
Page 1 / 1